How does CBH's PE Ratio compare to its peers?

CBH is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (21x).

How does CBH's PE Ratio compare vs other companies in the European Medical Equipment Industry?

CBH is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the European Medical Equipment industry average (29.7x).

What is CBH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBH is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the estimated Fair Price-To-Earnings Ratio (29.7x).

What is the Fair Price of CBH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CBH (€11.9) is trading below our estimate of [[fair value]] (€20.37)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Coloplast (DB:CBH) - Stock Price, News & Analysis

CBH Stock Overview

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details

CBH fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	3/6
Financial Health	2/6
Dividends	3/6

Rewards

Trading at 41.6% below our estimate of its fair value

Earnings are forecast to grow 12.85% per year

Earnings have grown 4.9% per year over the past 5 years

Risk Analysis

Debt is not well covered by operating cash flow

Dividend of 2.47% is not well covered by earnings or free cash flows

Coloplast A/S Competitors

Paul Hartmann

DB:PHH2

€713.9m

Siemens Healthineers

XTRA:SHL

€55.0b

Carl Zeiss Meditec

XTRA:AFX

€5.2b

Fresenius Medical Care

XTRA:FME

€12.2b

Price History & Performance

Summary of all time highs, changes and price drops for Coloplast
Historical stock prices
Current Share Price	DKK 11.90
52 Week High	DKK 12.90
52 Week Low	DKK 9.65
Beta	0.34
11 Month Change	1.71%
3 Month Change	-3.25%
1 Year Change	23.32%
33 Year Change	-21.92%
5 Year Change	n/a
Change since IPO	-8.07%

Recent updates

Shareholder Returns

	CBH	DE Medical Equipment	DE Market
7D	-1.7%	-3.7%	-0.5%
1Y	23.3%	-4.2%	8.3%

Return vs Industry: CBH exceeded the German Medical Equipment industry which returned -4.2% over the past year.

Return vs Market: CBH exceeded the German Market which returned 8.3% over the past year.

Price Volatility

Is CBH's price volatile compared to industry and market?
CBH volatility
CBH Average Weekly Movement	4.0%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: CBH has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: CBH's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1954	16,639	Kristian Villumsen	www.coloplast.com

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.

Coloplast A/S Fundamentals Summary

How do Coloplast's earnings and revenue compare to its market cap?
CBH fundamental statistics
Market cap	€26.86b
Earnings (TTM)	€677.26m
Revenue (TTM)	€3.62b

39.7x

P/E Ratio

7.4x

P/S Ratio

Is CBH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CBH income statement (TTM)
Revenue	DKK 27.03b
Cost of Revenue	DKK 8.76b
Gross Profit	DKK 18.27b
Other Expenses	DKK 13.22b
Earnings	DKK 5.05b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 04, 2025

Earnings per share (EPS)	22.44
Gross Margin	67.59%
Net Profit Margin	18.69%
Debt/Equity Ratio	120.6%

How did CBH perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

98%

Payout Ratio

Does CBH pay a reliable dividends?

See CBH dividend history and benchmarks

When do you need to buy CBH by to receive an upcoming dividend?
Coloplast dividend dates
Ex Dividend Date	Dec 09 2024
Dividend Pay Date	Dec 20 2024
Days until Ex dividend	20 days
Days until Dividend pay date	31 days

Does CBH pay a reliable dividends?

See CBH dividend history and benchmarks

CBH Stock Overview

Rewards

Risk Analysis

Coloplast A/S Competitors

DB:PHH2

€713.9m

XTRA:SHL

€55.0b

XTRA:AFX

€5.2b

XTRA:FME

€12.2b

Price History & Performance

Recent News & Updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021